Chemotherapy’s Low Response In Men, Suffered From Breast Cancer

5 Dariya News

16-Sep-2022

Cancer is like a tumour. Any person who has suffered from cancer has a very rare chance to get safe from this deadly disease. Because it is not only the disease that puts the patient in danger, but it also snatches the hope of living and joy from the cancer patient.

A study has revealed that those men who are affected by breast cancer have a very low response to neoadjuvant chemotherapy while curing or treating this cancer, before the surgery.

In women’s breast cancer Neoadjuvant Chemotherapy before surgery is presently the treatment for females while curing this disease. For women, this treatment for beating breast cancer is the most preserving treatment that protects them from breast cancer. 

The capability to assess this tumour's sensitivity to systemic therapy and tailor the treatment to be administered after surgery. On the other hand, it is not more effective for men who are suffering from breast cancer, despite minimal knowledge of its effectiveness.

Also Read: Heart attack vs cardiac arrest: Experts explain the surge

Those men who receive neoadjuvant chemotherapy have a lower proportion of pathological complete response (lack of all signs of cancer after treatment, which is determined by tissue samples).

“The chances of the tumour going away in full by the time surgery happens, as we compared with women”. “This was particularly true in patients with HER2 cancer. This could suggest a difference in tumour biology as well as sensitivity to treatment options,” said the study author, Dr. José Pablo Leone, a medical oncologist and director of Breast Cancer.

In this study, researchers analysed data from 385 men and 68,065 women with breast cancer who were treated with neoadjuvant chemotherapy. All patients had available information on their tumour subtype (HR+/HER2–, HR+/HER2+, HR–/HER2+, HR–/HER2–).

Also Read: How Many Thyroid Patients Are There In India? How Does This Problem Start? What To Eat In Thyroid?

The median time from neoadjuvant chemotherapy to surgery was 143 days in men compared with 148 days in women. According to the study authors of pathological complete responses than men with breast cancer, researchers have found that women with breast cancer had “twice the odds”.